How a unique DES platform translates into clinical differentiation with MiStent: from premise to proven effectiveness

Chairperson: P.W. Serruys

Objectives:

To know the science behind controlled elution and crystalline sirolimus
To hear and discuss late-breaking trial data from DESSOLVE III
To preview the MiStent OCT substudy and discuss the daily use of MiStent

Lectures

Session objectives

P.W. Serruys

Science of crystalline sirolimus

E. Edelman

DESSOLVE III data

R.J. De Winter

OCT data with cases

K. Milewski

Cases/clinical practice implications

G. Sardella

Session evaluation and key learnings